Finding a role for cancer vaccines in pancreatic cancer:a model of resilience

作     者：Gentry King Steven Green E.Gabriela Chiorean 

作者机构：Department of MedicineDivision of Medical OncologyUniversity of Washington School of MedicineSeattleWAUSA Clinical Research DivisionFred Hutchinson Cancer Research CenterSeattleWAUSA 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2022年第11卷第1期

页      面：115-118页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：chemotherapy cancer patients 

摘      要：Neoadjuvant chemotherapy with folinic acid,5-fluorouracil,irinotecan and oxaliplatin(FOLFIRINOX)or gemcitabine plus nab-paclitaxel(Gem-nabP)for 4 to 6 months,potentially followed by chemoradiotherapy and an attempt for surgical resection for select patients,represents the multidisciplinary care standard for borderline resectable(BRPC)and locally advanced pancreatic ductal adenocarcinoma(LAPC)patients with good performance status(1,2).With neoadjuvant therapy,resection rates average 65%and survival ranges from 22-29 months for BRPC,whereas LAPC patients have resection rates of 15-20%and survival of 16-24 months,respectively(3-5).